Atea Pharmaceuticals, Inc. (AVIR)
| Market Cap | 427.49M +81.4% |
| Revenue (ttm) | n/a |
| Net Income | -165.29M |
| EPS | -2.10 |
| Shares Out | 80.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 600,436 |
| Open | 5.21 |
| Previous Close | 5.26 |
| Day's Range | 5.17 - 5.37 |
| 52-Week Range | 2.78 - 6.45 |
| Beta | 0.29 |
| Analysts | Buy |
| Price Target | 9.42 (+76.74%) |
| Earnings Date | Aug 12, 2026 |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AVIR stock is "Buy." The 12-month stock price target is $9.42, which is an increase of 76.74% from the latest price.
News
Atea Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Phase III hepatitis C trials show strong efficacy and safety, with an eight-week regimen matching current standards and broad genotype coverage. Market research indicates high physician interest, and a focused sales strategy is planned. NDA filing is expected mid-next year, with robust financials supporting launch.
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral...
Atea Pharmaceuticals price target raised to $7 from $6 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Atea Pharmaceuticals (AVIR) to $7 from $6 and keeps an Equal Weight rating on the shares.
Atea Pharmaceuticals Earnings Call Transcript: Q2 2026
Phase III C-BEYOND trial met all endpoints, showing bemnifosbuvir's non-inferiority to standard care in a complex HCV population. Cash runway extends through 2027, with NDA submission planned for Q2 2027 and commercial launch targeted for mid-2028.
Atea Pharmaceuticals Earnings release: Q2 2026
Atea Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Atea Pharmaceuticals Slides: Q2 2026
Atea Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
Atea Pharmaceuticals Quarterly report: Q2 2026
Atea Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 12, 2026.
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral ...
Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints
Atea Pharmaceuticals (AVIR) announced topline results from C-BEYOND, its Phase 3 trial conducted in North America evaluating the once-daily fixed-dose combination of bemnifosbuvir and ruzasvir for the...
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ®), a Standard-of-Care, in First-Ever Successful Hea...
Atea Pharmaceuticals initiates AT-587 clinical trial
Atea Pharmaceuticals (AVIR) announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, for the treatment of hepatitis E virus infection. AT-587 is a proprietary oral antivi...
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver D...
Atea Pharmaceuticals completes patient enrollment in C-FORWARD trial
Atea Pharmaceuticals (AVIR) announced completion of patient enrollment in C-FORWARD, its Phase 3 clinical trial outside North America, evaluating the regimen of bemnifosbuvir and ruzasvir for the trea...
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the ...
Atea Pharmaceuticals Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation approval. Strategic updates highlighted progress in HCV and HEV programs, with strong financial resources supporting ongoing clinical milestones. No stockholder questions were raised.
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral a...
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral a...
Atea Pharmaceuticals Earnings Call Transcript: Q1 2026
Two pivotal phase III HCV trial readouts are expected in 2026, with strong enrollment progress and a robust financial position supporting operations through 2027. The pipeline expanded to include AT-587 for hepatitis E, with first-in-human studies planned mid-year.
Atea Pharmaceuticals Slides: Q1 2026
Atea Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Atea Pharmaceuticals Earnings release: Q1 2026
Atea Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Atea Pharmaceuticals Quarterly report: Q1 2026
Atea Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HC...
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral a...
Atea Pharmaceuticals Proxy statement: Proxy filing
Atea Pharmaceuticals filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.